Patent Application
20230048677
The invention belongs to the technical field of veterinary biological products, and in particular to an African swine fever virus chimeric protein, a vaccine composition containing the chimeric protein, a preparation method and use thereof.
African swine fever (ASF) is an acute, severe and highly contagious infectious disease caused by African swine fever virus (ASFV), with a high morbidity rate and mortality rate which can be as high as 100%, classified as a Class I animal disease in China. The first occurrence of the disease was first confirmed in Kenya, Africa in 1921. Since 2007, African swine fever has occurred, spread and become epidemic in many countries around the world. It was introduced to China in 2018, causing huge direct and indirect economic losses. It has been nearly a hundred years since the disease was discovered, but there are currently no approved vaccines or specific drugs in the world.
The difficulties in the research and development of African swine fever vaccines are that the virus has a large genome, with many proteins and a complex structure, which is difficult to cultivate on a large scale, prone to have variation during the passage; the mechanism of viral immune escape is unclear, and there is no substantial progress in conventional inactivated vaccines and live attenuated vaccines; in addition, the improper use of live attenuated vaccines may lead to biosafety risks of reversion to virulence and virus diffusion.
Therefore, the present invention used modern biological methods, analyzed the genes and proteins of pathogens and tested their immune protection ability, and developed protein engineering vaccines, which has effectively solved the problem of unsatisfactory immune effects of various vaccines at present.
In order to solve the deficiencies of the prior art, the present invention provides an African swine fever virus chimeric protein. When a vaccine is prepared by using the African swine fever virus chimeric protein, the immunization effect is excellent, and the problem of unsatisfactory immunization effect of various vaccines in the prior art is effectively solved.
One aspect of the present invention is to provide an African swine fever virus chimeric protein comprising:
(1) African swine fever virus p72 domain I, with an amino acid sequence as shown in SEQ ID NO.2;
(2) African swine fever virus p72 domain II, with an amino acid sequence as shown in SEQ ID NO.3;
(3) African swine fever virus p72 domain III, with an amino acid sequence as shown in SEQ ID NO. 4; and
(4) African swine fever virus antigenic protein;
(5) the African swine fever virus p72 domain I is located at the N-terminus of the chimeric protein, the African swine fever virus p72 domain III is located at the C-terminus of the chimeric protein, and the African swine fever virus p72 domain II is located between the domain I and the domain III, the African swine fever virus antigenic protein is located between the domain I and the domain II and/or between the domain II and the domain III.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is at least one of p54, p30, CD2v and p12 protein fragments.
As an embodiment of the present invention, the p54 protein fragment of the present invention is selected from any one or more of SEQ ID NO.5, 6, 7, 8, 9, 10, 11, and 12.
As an embodiment of the present invention, the p30 protein fragment of the present invention is selected from any one or more of SEQ ID NO. 13, 14, 15, 16, 17, 18, and 19.
As an embodiment of the present invention, the CD2v protein fragment of the present invention is selected from any one or more of SEQ ID NO. 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30.
As an embodiment of the present invention, the p12 protein fragment of the present invention is selected from any one or more of SEQ ID NO. 31, 32, 33, 34, 35, 36, and 37.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is a p54+p30 protein fragment, and the p54+p30 protein fragment is selected from any one or more of SEQ ID NO. 38, 39 and 40.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is a p54+CD2v protein fragment, and the p54+CD2v protein fragment is selected from any one or more of SEQ ID NO. 41, 42 and 43.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is a p30+CD2v protein fragment, and the p30+CD2v protein fragment is selected from any one or more of SEQ ID NO. 44, 45 and 46.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is a p30+p12 protein fragment, and the p30+p12 protein fragment is selected from any one or more of SEQ ID NO. 47, 48 and 49.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is a CD2v+p12 protein fragment, and the CD2v+p12 protein fragment is selected from any one or more of SEQ ID NO. 50, 51 and 52.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is a p54+p30+CD2v protein fragment, and the p54+p30+CD2v protein fragment is selected from any one or more of SEQ ID NO. 53, 54 and 55.
As an embodiment of the present invention, the African swine fever virus antigenic protein contained in the African swine fever virus chimeric protein of the present invention is p54+p30+CD2v+p12 protein fragment, and the p54+p30+CD2v+p12 protein fragment is selected from any one or more of SEQ ID NO. 56, 57 and 58.
As an embodiment of the present invention, the African swine fever virus chimeric protein of the present invention further comprises a T cell immune activation epitope, the T cell immune activation epitope include but are not limited to a cholera toxoid T cell epitope and/or a diphtheria toxin T cell epitope and/or a tetanus toxoid T cell epitope and/or an Escherichia coli heat-labile enterotoxin T cell epitope.
As an embodiment of the present invention, the diphtheria toxin T cell epitope of the present invention is selected from any one or more of SEQ ID NO.59, 60, 61, 62, 63, 64 and 65.
As an embodiment of the present invention, the tetanus toxoid T cell epitope of the present invention is selected from any one or more of SEQ ID NO.66, 67, 68, 69, 70, 71, 72, 73, 74 and 75.
As an embodiment of the present invention, the African swine fever virus chimeric protein of the present invention further includes a flexible linking peptide, and the flexible linking peptide has a length of 4-10 amino acids. The flexible linking peptide can make the chimeric protein have better affinity, mainly due to the fact that the flexible linking peptide increases the space between the structural functional domains, eliminates or reduces the spatial physical hindrance between adjacent structural functional domains, increases the relative independence of each structural functional domain of the chimeric protein, and at the same time also increases the structural stability and biological function of each functional region of the chimeric protein.
As an embodiment of the present invention, the flexible linking peptide selected in the present invention is GGGS.
A second aspect of the present invention is to provide a method for preparing an African swine fever virus chimeric protein comprising:
(1) artificially synthesizing a gene of the African swine fever virus chimeric protein, and linking it to a cloning vector, that is, a cloning vector of the chimeric protein by means of genetic engineering;
(2) constructing an expression vector comprising the gene of the chimeric protein, that is, an expression vector of the chimeric protein by digesting the constructed cloning vector of the chimeric protein and an expression vector with enzyme;
(3) introducing the expression vector of the chimeric protein into the recipient bacteria to induce expression, and identifying the expressed chimeric protein to obtain the African swine fever virus chimeric protein.
As an embodiment of the present invention, the African swine fever virus chimeric protein of the present invention can be prepared by a prokaryotic expression system, a eukaryotic expression system or a chemical synthesis method.
The third aspect of the present invention is to provide a polynucleotide encoding the African swine fever virus chimeric protein.
The fourth aspect of the present invention is to provide an expression vector containing the polynucleotide sequence. According to common knowledge in the art, those skilled in the art can obtain the nucleotide sequence encoding the corresponding amino acid sequence according to the amino acid sequence of the African swine fever chimeric protein disclosed above, and then obtain the polynucleotide.
A fifth aspect of the present invention is to provide a genetically engineered African swine fever virus vaccine composition, comprising an immune amount of the African swine fever virus chimeric protein and a pharmaceutically acceptable carrier.
As an embodiment of the present invention, in the genetically engineered African swine fever virus vaccine composition of the present invention, the content of the African swine fever virus chimeric protein is 100-300 μg/ml.
African swine fever virus chimeric protein content can be selected from 100 μg/ml, 110 μg/ml, 120 μg/ml, 130 μg/ml, 140 μg/ml, 150 μg/ml, 160 μg/ml, 170 μg/ml, 180 μg/ml, 190 μg/ml, 200 μg/ml, 210 μg/ml, 220 μg/ml, 230 μg/ml, 240 μg/ml, 250 μg/ml, 260 μg/ml, 270 μg/ml, 280 μg/ml, 290 μg/ml and 300 μg/ml.
As an embodiment of the present invention, in the genetically engineered African swine fever virus vaccine composition of the present invention, the pharmaceutically acceptable carrier comprises an adjuvant which comprises one or more of (1) white oil, alhydrogel adjuvant, saponins, Avridine, DDA; (2) water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion; or (3) polymers of acrylic or methacrylic acid, copolymers of maleic anhydride and alkenyl derivative; and the R1131 adjuvant system, Block co-polymer, SAF-M, monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli, cholera toxin, IMS 1314, muramyl dipeptide, Montanide ISA 206, and Gel adjuvant; preferably, the saponin is Quil A, QS-21 or GPI-0100.
The content of the adjuvant is 5%-60% V/V, preferably 30%-60% V/V, more preferably 50% V/V.
As an embodiment of the present disclosure, the pharmaceutically acceptable carrier includes drugs, immunostimulants, antioxidants, surfactants, colorants, volatile oils, buffers, dispersants, propellants and preservatives; the immunostimulants include α-interferon, β-interferon, γ-interferon, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF) and interleukin 2 (IL2).
Methods well known in the art can be used to prepare such compositions.
The sixth aspect of the present invention is to provide a use of the genetically engineered African swine fever virus vaccine composition for the manufacture of a medicament for prevention of African swine fever.
The present invention has the following outstanding advantages: The African swine fever virus chimeric protein of the present invention uses the African swine fever virus p72 protein as the backbone for the first time, and well displays the antigenic epitopes of the p54, p30, CD2v and p12 proteins, has good immune effect, and can produce significant humoral and cell-mediated immunity, which effectively solve the problem of poor immunogenicity currently faced by African swine fever virus vaccines; the vaccine composition can be expressed in a large amount by means of genetic engineering, which not only takes short time, but also easy to produce on a large scale, and has no biological safety risk.
Embodiments of the present invention will be described hereinafter.
An “Antigen” refers to a substance that can induce an immune response in the body, that is, it can be specifically recognized and bound by the antigen receptor (TCR/BCR) on the surface of T/B lymphocytes, activate T/B cells, and make them proliferate and differentiate, produce immune response products (sensitized lymphocytes or antibodies), and can specifically bind to the corresponding products in vitro and in vivo.
The terms “vaccine” and “vaccine composition” as used in the present invention refer to a pharmaceutical composition containing an African swine fever virus chimeric protein, which can induce, stimulate or enhance the immune response of a swine against African swine fever virus.
The term “immune amount” should be understood as an “immunologically effective amount,” also refers to an immunoprotective amount or an effective amount to produce an immune response, which is an amount of antigen effective to induce an immune response in a recipient, which immune amount is sufficient to prevent or ameliorate signs or symptoms of a disease including adverse health effects or complications of the disease. The immune response may be sufficient for diagnostic purposes or other tests or may be suitable for use in preventing signs or symptoms of a disease, including adverse health consequences caused by an infection caused by a pathogen, or complications of the disease. Humoral immunity or cell-mediated immunity or both may be induced. The immune response of the animal to the immunogenic composition may be assessed indirectly, for example, by measuring antibody titers and analyzing lymphocyte proliferation, or directly by monitoring signs or symptoms after challenge with wild-type strains, while protective immunity provided by the vaccine may be assessed by measuring, for example, clinical signs of subjects such as mortality, reduction in morbidity, temperature values, and overall physiological condition and overall health and performance of the subjects. The immune response may include, but are not limited to induction of cellular and/or humoral immunity.
The term “pharmaceutically acceptable carrier” refers to all components other than the ASFV chimeric antigen in the vaccine composition of the present disclosure which are carriers or diluents that do not cause significant irritation to an organism and do not abrogate the biological activity and properties of the administered compounds, preferably an adjuvant. The term “adjuvant” may include a compound selected from a group consisting of alhydrogel adjuvant, saponins e.g., Quil A. QS-21 (Cambridge Biotech Inc., Cambridge Mass.), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, Ala.), water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion, the polymers of acrylic or methacylic acid and the copolymers of maleic anhydride and alkenyl derivative. The term “emulsion” may be based in particular on light liquid paraffin oil (European Pharmacopoeia type); isoprenoid oil such as squalane or squalene oil resulting from the oligomerization of alkenes, in particular of isobutene or decene; esters of acids or of alcohols containing a linear alkyl group, more particularly plant oils, ethyl oleate, propylene glycol di-(caprylate/caprate), glyceryl tri-(caprylate/caprate) or propylene glycol dioleate; esters of branched fatty acids or alcohols, in particular isostearic acid esters. The oil is used in combination with emulsifier to form the emulsion. The emulsifiers are preferably nonionic surfactants, in particular esters of sorbitan, of mannide (e.g. anhydromannitol oleate), of glycol, of polyglycerol, of propylene glycol and of oleic, isostearic, ricinoleic or hydroxy-stearic acid, which are optionally ethoxylated, and polyoxypropylene-polyoxyethylene block copolymers, in particular the Pluronic products, especially L121. See Hunter et al., The Theory and Practical Application of Adjuvants (Ed. Stewart-Tull, D. E. S). John Wiley and Sons, NY, pp 51-94 (1995) and Todd et al. Vaccine 15:564-570 (1997). For example, it is possible to use the SPT emulsion described on page 147 of “Vaccine Design, The Subunit and Adjuvant Approach” edited by M. Powell and M. Newman, Plenum Press, 1995, and the emulsion MF59 described on page 183 of the same book. The term “polymers of acrylic or methacrylic acid” preferably are the polymers of acrylic or methacrylic acid which are cross-linked, especially with polyalkenyl ethers of sugars or polyalcohols. These compounds are known by the term carbomer (Trade name, Carbopol) (Phameuropa Vol. 8, No. 2, June 1996). Persons skilled in the art can also refer to U.S. Pat. No. 2,909,462 which describes such acrylic polymers cross-linked with a polyhydroxylated compounds having at least 3 hydroxyl groups, preferably not more than 8, the hydrogen atoms of at least three hydroxyls being replaced by unsaturated aliphatic radicals having at least 2 carbon atoms. The preferred radicals are those containing from 2 to 4 carbon atoms, e.g. vinyls, allyls and other ethylenically unsaturated groups. The unsaturated radicals may themselves contain other substituents, such as methyl. The products sold under the name Carbopol, (BF Goodrich, Ohio. USA) are particularly appropriate. They are cross-linked with an allyl sucrose or with allyl pentaerythritol. Among them, there may be mentioned Carbopol 974P, 934P and 971 P, most preferably Carbopol 971P. For the term “copolymers of maleic anhydride and alkenyl derivative”, EMA (Monsanto), which is the copolymer of maleic anhydride and ethylene, can also be considered. The dissolution of these polymers in water leads to an acid solution that will be neutralized, preferably to physiological pH, in order to give the adjuvant solution, into which the immunogenic, immunological or vaccine composition itself will be incorporated. The term “adjuvant” includes, but is not limited to, the RIBI adjuvant system (Ribi Inc.), Block co-polymer (CytRx, Atlanta Ga.), SAF-M (Chiron, Emeryville Calif.), monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli (recombinant or otherwise), cholera toxin, IMS 1314, muramyl dipeptide, and Gel adjuvant among many others. Preferably, the adjuvant includes one or more of mineral oil, alhydrogel adjuvant, saponins, water-in-oil emulsion, oil-in-water emulsion, water-in-oil-in-water emulsion, the polymers of acrylic or methacylic acid, the copolymers of maleic anhydride and alkenyl derivative, the RIBI adjuvant system, Block co-polymer, SAF-M, monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E. coli, cholera toxin, IMS 1314, muramyl dipeptide, Montanide ISA 206 and Gel adjuvant.
The term “prevention” when referring to ASFV infection refers to the inhibition of ASFV replication, inhibition of ASFV transmission or prevention of ASFV colonization in its host, and alleviation a disease or symptoms of disease of ASFV infection.
The description of the present disclosure is further provided as follows with reference to the specific embodiments, and features and advantages of the present disclosure will become more apparent from the following description. However, these embodiments are merely exemplary and do not limit the scope of the present disclosure in any way. It should be understood by a person skilled in the art that modifications or alternatives to details and forms of the technical solution of the present disclosure without deviation from the spirit and scope of the present disclosure will be allowed, while those modifications and alternatives should all fall within the scope of the present disclosure.
The chemical reagents used in the examples of the present disclosure are of analytical grade and are purchased from Sinopharm Group Co. Ltd. The experimental methods described in the present disclosure are conventional methods unless otherwise specified. The biological materials are commercially available unless otherwise specified.
The corresponding nucleotide sequence encoding the amino acid sequence of the p72 protein shown in SEQ ID NO.1 was synthesized by GENEWIZ, Inc., and the synthesized nucleotides were cloned into the pET28a vector and renamed as the recombinant plasmid pET28a-p72.
Similarly, the African swine fever virus p72 domain I shown by SEQ ID NO.2 in the sequence listing, the African swine fever virus p72 domain II shown by SEQ ID NO.3 in the sequence listing, and the African swine fever virus p72 domain III shown by SEQ ID NO.4 in the sequence listing were linked by a flexible linking peptide, wherein the African swine fever virus p72 domain I is located at the N-terminus, domain III is located at the C-terminus, and domain II is located between domain I and domain III.
The corresponding encoding nucleotide sequence was synthesized by GENEWIZ, Inc., and the synthesized nucleotides were cloned into the pET28a vector and renamed as the recombinant plasmid pET28a-Δp72.
The above recombinant plasmids pET28a-p72 and pET28a-Δp72 were transformed into competent Escherichia coli BL21 (DE3), respectively, to construct expression strain 1 and expression strain 2, which were inoculated into 50 ml of kanamycin-resistant LB liquid medium at 37° C., cultivated with shaking at 230 rpm for 12 hours, and transferred to 1 L of LB liquid medium and cultured at 37° C. to prepare seed broth for fermentation.
The fermentation tank is a 50 L fermentation tank (Shanghai Baoxing Bio-Engineer Equipment Co., Ltd.). 30 L of culture medium was prepared and put into the fermentation tank, sterilized at 121° C. for 30 minutes. On the next day, 3 L of seed broth was introduced to the fermentation tank, and when the concentration of cell culture reached about 10 OD600, the culture temperature was lowered to 25° C., and IPTG was added to induce expression for 12 hours. When the fermentation density was about 40 (OD600), the culture was stopped and the bacteria were collected by centrifugation.
The bacteria were resuspended, and broken 4 times at a pressure of 800 bar by using a homogenizer, which was then centrifuged at 13500 rpm for 40 min. The supernatant was retained and detected by 15% SOS-PAGE electrophoresis. The protein was roughly purified by ammonium sulfate fractional precipitation, followed by chromatography, and the purified protein was subjected to SOS-PAGE electrophoresis which showed that the target protein was purified and enriched.
The full-length p72 protein and truncated p72 protein prepared in Example 1 were added to an adjuvant, which was continuously stirred by an emulsifier at 800 rpm for 12 minutes during the process of adding, mixed well and stored at 4° C. Vaccine compositions containing full-length p72 protein or truncated p72 protein were prepared. Adjuvants suitable for use in the present disclosure may be adjuvants known to those skilled in the art. In the present disclosure, a biphasic adjuvant (water-in-oil-in-water emulsion), for example adjuvant ISA 206 (SEPPIC, France) was selected. The specific ratio of each component in the prepared vaccine is shown in Table 1.
15 healthy and susceptible piglets negative for ASFV antibody and antigen with a weight of about 20 kg were selected and randomly divided into 3 groups, 5 pigs per group. Group 1 was immunized with vaccine 1, group 2 with immunized vaccine 2, and the third group was a blank control group. The immunization route of the immunization groups was intramuscular neck injection of 2 ml of vaccine, and the control group was immunized with the same amount of PBS+adjuvant. Immunization was performed twice with an interval of 14 days. Before the 1st immunization and on the 14th day after second immunization, blood samples were taken from each of the piglets.
An ELISA plate was coated with inactivated whole African swine fever virus antigen (purchased from EUROPEAN UNION REFERENCE LABORATORY FOR AFRICAN SWINE FEVER, URL-ASF) overnight at 4° C.; washed twice with phosphate buffered saline after discarding the coating solution; added with 5% bovine serum albumin BSA and blocked for 2 hours at 37° C.; washed twice with phosphate buffered saline after discarding the coating solution, and patted dry.
Sample Diluent: phosphate buffered saline.
Wash solution: phosphate buffered saline containing 0.05% v/v Tween-20.
Secondary antibody: Enzyme-labeled goat anti-pig secondary antibody, which was used with a dilution of 1:2000.
Chromogenic solution: including solution A and solution B, among which, solution A is 20 mg of TMB added with 10 ml of anhydrous ethanol, diluted to 100 ml with ddH2O, and aseptically distributed and packaged after mixing; solution B is 2.1 g of citric acid and 42.82 g of anhydrous Na2HPO, 0.64 ml of 0.75% urea hydrogen peroxide, diluted to 100 ml with ddH2O, and aseptically distributed and packaged after mixing.
Stop solution: 2M H2SO4.
During testing, 50 μl of phosphate buffered saline was added to the wells of ELISA plate, then 50 μl of serum to be tested was added, followed by adding of negative and positive controls, incubated at 37° C. for 30 minutes, the plate was washed three times with wash solution, and goat anti-pig enzyme-labeled antibody was diluted with PBS by 1:2000 and added 100 μl/well into the reaction plate, and incubated at 37° C. for 30 minutes. The plate was washed three times with wash solution, 50 μl of chromogenic solution A and 50 μl of chromogenic solution B were added to each well, and the color was developed at 37° C. for 10 minutes. The absorbance OD450 nm was read with a microplate reader after adding of 50 μ/well of the stop solution for stopping reactions, and the judgment was made according to the result.
Judgment standard: considered as positive when OD value is above 0.19, negative when OD value is less than 0.19.
The test results are shown in Table 2.
The results shows that both full-length and truncated ASFV p72 protein antibodies were tested as positive, and there was no difference in the values of antibody detection. It shows that the truncation of the AFSV p72 protein of the present invention does not affect its immunogenicity, and provides the possibility for the p72 protein to be used as a backbone to construct a chimeric protein.
By analyzing the structure of the p72 protein of African swine fever virus, the inventors creatively truncated the protein, which still maintains the relative stability of the spatial structure of the protein, without affecting its immunogenicity. To this end, a truncated p72 protein was determined as the backbone of the chimeric protein of the present invention.
At the same time, the inventors have screened the following sequences after extensive experimental research combined with the analysis of the antigenic epitope of the immunogenic protein of African swine fever virus, and the chimeric protein can generate a higher immunogenic response when the African swine fever virus antigenic proteins contained in the chimeric protein is at least one of p54, p30, CD2v and p12 protein fragments.
The p54 protein fragment is selected from any one or more of SEQ ID NO.5, 6, 7, 8, 9, 10, 11 and 12;
The p30 protein fragment is selected from any one or more of SEQ ID NO. 13, 14, 15, 16, 17, 18 and 19;
CD2v protein fragments are selected from any one or more of SEQ ID NO. 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30;
The p12 protein fragment is selected from any one or more of SEQ ID
NO. 31, 32, 33, 34, 35, 36 and 37.
Referring to the method of Example 1, SEQ ID NOs. 7 and 13 in Example 3 were inserted between the African swine fever virus p72 truncated protein domain I and domain II, and between domain II and domain III, respectively, to form four chimeric proteins, that is, from N-terminus to C-terminus: SEQ ID NO.2+SEQ ID NO.7+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.7+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.13+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.13+SEQ ID NO.4. Expression strain 3, expression strain 4, expression strain 5 and expression strain 6 were constructed.
The expression strains 3, 4, 5, and 6 were cultured in a fermenter, respectively, and the proteins were collected and purified.
The four proteins expressed and collected in Example 4 were added with an adjuvant according to the method in Example 2 to prepare vaccine compositions. The specific component ratio of each vaccine composition is shown in Table 3.
25 healthy and susceptible piglets negative for ASFV antibody and antigen with a weight of about 20 kg were selected and randomly divided into 5 groups, 5 piglets per group. Groups 4-7 were immunized with vaccines 3-6 respectively, and group 8 was a blank control group. The immunization route of the immunization groups was intramuscular neck injection of 2 ml of vaccine, and the control group was immunized with the same amount of PBS+adjuvant. Immunization was performed twice with an interval of 14 days. Before the 1st immunization and on the 14th day after second immunization, blood samples were taken from each of the piglets. The test results are shown in Table 4.
The results shows that no matter the truncated p72 protein as the backbone or the inserted p54 protein fragment, or the whole chimeric protein, the four African swine fever virus chimeric proteins had certain immunogenicity; the immunogenicity of the chimeric proteins was better; there was no difference in immunogenicity between different insertion sites. It shows that different insertion sites had no effect on the immunogenicity of the African swine fever virus chimeric protein; after inserting the African swine fever virus antigenic protein, the immunogenicity of the truncated p72 protein as the backbone was not affected.
SEQ ID NOs. 9, 16, 22, 23 and 32 in Example 3 were inserted between the truncated African swine fever virus p72 protein domain I and domain II, respectively, and SEQ ID NOs. 10, 18, 19, 25 and 35 were inserted between domain II and domain III, respectively, to form 10 chimeric proteins, that is, from N-terminus to C-terminus: SEQ ID NO.2+SEQ ID NO.9+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.16+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.22+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.23+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.32+SEQ ID NO.3+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.10+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.18+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.19+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.25+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.35+SEQ ID NO.4. Expression strains 7-16 were constructed.
The expression strains 7-16 were cultured in a fermenter, respectively, and the proteins were collected and purified.
The 10 proteins expressed and collected in Example 6 were added with an adjuvant to prepare vaccine compositions with reference to the method of Example 2. The specific component ratios of each vaccine composition are shown in Tables 5 and 6.
55 healthy and susceptible piglets negative for ASFV antibody and antigen with a weight of about 20 kg were selected and randomly divided into 11 groups, 5 piglets per group. Groups 9-18 were immunized with vaccines 7-16 respectively, and group 19 was a blank control group. The immunization route of the immunization groups was intramuscular neck injection of 2 ml of vaccine, and the control group was immunized with the same amount of PBS+adjuvant. Immunization was performed twice with an interval of 14 days. Before the 1st immunization and on the 14th day after second immunization, blood samples were taken from each of the piglets. The test results are shown in Table 7.
The results show that all 10 African swine fever virus chimeric proteins had certain immunogenicity and were positive for antibodies; there was no difference between the immunogenicity of the chimeric protein vaccine compositions at different insertion sites.
Further, SEQ ID NOs. 5, 6, 8, 12, 14, 20, 21, 29, 30, and 31 in Example 3 were inserted between domain I and domain II of truncated African swine fever virus p72 protein, respectively and SEQ ID NOs. 11, 15, 17, 24, 26, 27, 28, 33, 34, 36, and 37 were inserted between domain II and domain III of truncated African swine fever virus p72 protein, respectively, to form 21 chimeric proteins. Expression strains were constructed to express the proteins, and the vaccine compositions were prepared by referring to the method of Example 2. The assay on piglets showed that the test results of the antibody on 14 days after the second immunization were between 0.622 and 0.664, and the results were positive. It is proved that the p54 protein fragment, the p30 protein fragment, the CD2v protein fragment and the p12 protein fragment selected by the present invention as the antigenic proteins of the chimeric protein all have certain immunological activities, and it is further shown that different insertion sites have no effect on the immunogenicity of African swine fever virus chimeric proteins.
In this example, any two protein fragments screened by the present invention were inserted between domain II and domain III of truncated African swine fever virus p72 protein, which can alternatively be inserted between domain I and domain II of truncated African swine fever virus p72 protein, or can also be inserted between domain I and domain II and between domain II and domain III at the same time without any specific limitation. The schematic diagram is shown in
The expression strains 17-31 were cultured in a fermenter, respectively, and the proteins were collected and purified.
The 15 proteins expressed and collected in Example 8 were added with an adjuvant to prepare vaccine compositions with reference to the method of Example 2. The specific component ratios of each vaccine composition are shown in Tables 8, 9, and 10.
80 healthy and susceptible piglets negative for ASFV antibody and antigen with a weight of about 20 kg were selected and randomly divided into 16 groups, 5 piglets per group. Groups 20-34 were immunized with vaccines 17-31 respectively, and group 35 was a blank control group. The immunization route of the immunization groups was intramuscular neck injection of 2 ml of vaccine, and the control group was immunized with the same amount of PBS+adjuvant. Immunization was performed twice with an interval of 14 days. Before the 1st immunization and on the 14th day after second immunization, blood samples were taken from each of the piglets. The test results are shown in Table 11.
The results show that the 15 African swine fever virus chimeric proteins all had good immunogenicity and were positive for antibodies. It shows that a chimeric protein inserted with two protein fragments has better immunogenicity than a chimeric protein inserted with a single protein fragment.
Referring to the method of Example 1, any three or four of the p54 protein fragment, p30 protein fragment, CD2v protein fragment, and p12 protein fragment in Example 3 were selected to form SEQ ID NO. 53, 54, 55, 56, 57, 58, and inserted between domain II and domain III of truncated African swine fever virus p72 protein, respectively, to form six chimeric proteins, namely, that is, from the N-terminus to the C-terminus: SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.53+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.54+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.55+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.56+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.57+SEQ ID NO.4, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.58+SEQ ID NO.4. Expression strains 32-37 were constructed.
The expression strains 32-37 were cultured in a fermenter, respectively, and the proteins were collected and purified.
The 6 proteins expressed and collected in Example 10 were added with an adjuvant to prepare vaccine compositions with reference to the method of Example 2. The specific component ratio of each vaccine composition is shown in Table 12.
35 healthy and susceptible piglets negative for ASFV antibody and antigen with a weight of about 20 kg were selected and randomly divided into 7 groups, 5 piglets per group. Groups 36-41 were immunized with vaccines 32-37 respectively, and group 42 was a blank control group. The immunization route of the immunization groups was intramuscular neck injection of 2 ml of vaccine, and the control group was immunized with the same amount of PBS+adjuvant. Immunization was performed twice with an interval of 14 days. Before the 1st immunization and on the 14th day after second immunization, blood samples were taken from each of the piglets. The test results are shown in Table 13.
The results show that the 6 African swine fever virus chimeric proteins all had good immunogenicity and were positive for antibodies. It shows that a chimeric protein inserted with more than two protein fragments has better immunogenicity than a chimeric protein inserted with a single protein fragment or two protein fragments.
Referring to the method of Example 1, any one or more of the p54 protein fragment, p30 protein fragment, CD2v protein fragment, and p12 protein fragment in Example 3 were linked to T cell immune activation epitopes, including but not limited to cholera toxoid T cell epitopes and/or diphtheria toxin T cell epitopes and/or tetanus toxoid T cell epitopes and/or Escherichia coli heat-labile enterotoxin T cell epitopes, and then inserted into domain II and domain III of truncated African swine fever virus p72 protein to form a chimeric protein. In this example, two or three of the p54 protein fragment, p30 protein fragment, CD2v protein fragment, and p12 protein fragment in Example 3 were selected to form SEQ ID NO.38, 39, 45, 47, 52, and 54 which were linked to the diphtheria toxin T cell epitope SEQ ID NO.61 or the tetanus toxoid T cell epitope SEQ ID NO.70, respectively inserted between domain II and domain III of truncated African swine fever virus p72 protein, to form 12 chimeric proteins, that is, from the N-terminus to the C-terminus: SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.38+SEQ ID NO.4+SEQ ID NO.61, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.39+SEQ ID NO.4+SEQ ID NO.61, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.45+SEQ ID NO.4+SEQ ID NO.61, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.47+SEQ ID NO.4+SEQ ID NO.61, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.52+SEQ ID NO.4+SEQ ID NO.61, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.54+SEQ ID NO.4+SEQ ID NO.61, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.38+SEQ ID NO.4+SEQ ID NO.70, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.39+SEQ ID NO.4+SEQ ID NO.70, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.45+SEQ ID NO.4+SEQ ID NO.70, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.47+SEQ ID NO.4+SEQ ID NO.70, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.52+SEQ ID NO.4+SEQ ID NO.70, SEQ ID NO.2+SEQ ID NO.3+SEQ ID NO.54+SEQ ID NO.4+SEQ ID NO.70. Expression strains 38-49 were constructed.
The expression strains 38-49 were cultured in a fermenter, respectively, and the proteins were collected and purified.
The 12 proteins expressed and collected in Example 12 were added with an adjuvant to prepare vaccine compositions with reference to the method of Example 2. The specific component ratios of each vaccine composition are shown in Tables 14, 15 and 16.
95 healthy and susceptible piglets negative for ASFV antibody and antigen with a weight of about 20 kg were selected and randomly divided into 19 groups, 5 piglets per group. Groups 43-60 were immunized with vaccines 38-55 respectively, and group 61 was a blank control group. The immunization route of the immunization groups was intramuscular neck injection of 2 ml of vaccine, and the control group was immunized with the same amount of PBS+adjuvant. Immunization was performed twice with an interval of 14 days. Before the 1st immunization and on the 14th day after second immunization, blood samples were taken from each of the piglets. The test results are shown in Table 17.
The results show that the 12 ASFV chimeric proteins containing T cell immune activation epitopes all had good immunogenicity and were positive for antibodies. Their immunogenicity is better compared with the African swine fever virus chimeric proteins without adding T cell immune activation epitope verified in Example 9 and Example 11. It shows that the addition of T cell immune activation epitopes helped to further enhance the immune response.
Peripheral blood lymphocytes were isolated from the peripheral blood of pigs from groups 20, 21, 27, 29 and 34 collected in Example 9, group 37 collected in Example 11, and groups 49-61 collected in Example 13, and detected by using Swine IFN Cytoset ELISPOT detection kit from Biosource Europe, and the number of spots were counted. The test results are shown in Table 18.
The results show that the African swine fever virus chimeric protein vaccine composition to which the T cell immune activation epitope is added can better stimulate the production of cell-mediated immunity, which is significantly higher than that of the African swine fever virus chimeric protein vaccine composition without the addition of T cell immune activation epitopes.
It shows that adding T cell immune activation epitope on the basis of the chimeric protein of the present invention is beneficial for cellular immune response.
Those are only preferred embodiments of the present invention as described above, which cannot be used to limit the present invention in any forms. Although the present invention has been revealed as described above in the form of the preferred embodiments, they are not intended to limit the present invention. Any skilled in the art can make several changes to the above technical content or modify the above technical content as equivalent embodiments with equivalent substitution, without departing from the technical scope of the present invention. Any simple change, equivalent substitution or modification etc. which are made to the above embodiments, based on the technical nature of the present invention, without departing from the content of technical solution of the present invention, should fall within the scope of protection of the present invention.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202010180036.8 | Mar 2020 | CN | national |
This application is a National Stage application of International Application No. PCT/CN2021/079792 filed on Mar. 9, 2021, which claims priority to Chinese Application No. 202010180036.8 filed Mar. 13, 2020.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2021/079792 | 3/9/2021 | WO |
